CytoDyn Inc. Net Income (Loss) Available to Common Stockholders, Diluted
CytoDyn Inc. (CYDY) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$44.18 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-08-31.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-31
- CytoDyn Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-05-31 was -$10.24M.
- CytoDyn Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-02-28 was -$5.05M.
- CytoDyn Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-11-30 was -$22.98M.
- CytoDyn Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-08-31 was -$5.91M, a 130.75% decline year-over-year.
- CytoDyn Inc. net income (loss) available to common stockholders, diluted for fiscal 2026 was -$44.18M, a 2053.14% decline from fiscal 2025.
- CytoDyn Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was $2.26M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$10.24M derived: 10-K 12 month − S-1 9 month · filed 2026-08-31 | -$15.29M derived: sum of 2 quarters · filed 2026-08-31 | -$38.27M derived: sum of 3 quarters · filed 2026-08-31 | -$44.18M 10-K · filed 2026-08-31 |
| 2026-02-28 | -$5.05M 10-Q · filed 2026-04-08 | -$28.03M derived: sum of 2 quarters · filed 2026-04-08 | -$33.94M S-1 · filed 2026-04-22 | -$40.28M derived: sum of 4 quarters · filed 2026-08-31 |
| 2025-11-30 | -$22.98M 10-Q · filed 2026-01-09 | -$28.89M 10-Q · filed 2026-01-09 | -$35.22M derived: sum of 3 quarters · filed 2026-08-31 | -$40.34M derived: sum of 4 quarters · filed 2026-08-31 |
| 2025-08-31 | -$5.91M 10-Q · filed 2025-10-10 | -$12.25M derived: sum of 2 quarters · filed 2026-08-31 | -$17.37M derived: sum of 3 quarters · filed 2026-08-31 | -$22.51M derived: sum of 4 quarters · filed 2026-08-31 |
| 2025-05-31 | -$6.33M derived: 10-K 12 month − S-1 9 month · filed 2026-08-31 | -$11.46M derived: sum of 2 quarters · filed 2026-08-31 | -$16.59M derived: sum of 3 quarters · filed 2026-08-31 | $2.26M 10-K · filed 2026-08-31 |
| 2025-02-28 | -$5.12M 10-Q · filed 2026-04-08 | -$10.26M derived: sum of 2 quarters · filed 2026-04-08 | $8.60M S-1 · filed 2026-04-22 | |
| 2024-11-30 | -$5.14M 10-Q · filed 2026-01-09 | $13.72M 10-Q · filed 2026-01-09 | ||
| 2024-08-31 | $19.23M 10-Q · filed 2025-10-10 | |||
| 2023-08-31 | -$11.94M 10-Q · filed 2024-10-15 |